Glycolysis has long been considered as the major metabolic process for energy production
and anabolic growth in cancer cells. Although such a view has been instrumental for the …

The broadly active glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) has been
studied for 60 years as a potential anticancer therapeutic. Clinical studies of DON in the …

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often
ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated …

Introduction Metabolomics is a well-established tool in systems biology, especially in the top–
down approach. Metabolomics experiments often results in discovery studies that provide …

Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer that is highly refractory to
the current standards of care. The difficulty in treating this disease is due to a number of …

Cancers have an altered metabolism, and there is interest in understanding precisely how
oncogenic transformation alters cellular metabolism and how these metabolic alterations …

Mitochondrial function is important for aspartate biosynthesis in proliferating cells. Here, we
show that mitochondrial aspartate export via the aspartate-glutamate carrier 1 (AGC1) …

Altered cellular metabolism is a hallmark of cancer. Cancer cells express isoforms of
metabolic enzymes that may constitute therapeutic targets. Glutaminase controls glutamine …

A selective palladium-catalyzed trifluoroethylation reaction of indoles has been developed.
The CH bond activation process, using CF3CH2I as the fluoroalkyl source, can be employed …

The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no
clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines …